Philip Macilwraith, Mark Shackleton, Andrew Haydon, D. Nadebaum, V. Mar, V. Naranbhai, Martin H. Cherk
tlooto Summary
Pseudoprogression on 18F-FDG PET/CT occurred in approximately 2.5% of metastatic melanoma patients commencing immunotherapy with an average time to subsequent confirmed response of ~6 months, highlighting the importance of not ceasing immunotherapy prematurely based on early 18F-FDG PET/CT findings.
Abstract
To evaluate the incidence of pseudoprogression on 18F‐FDG PET/CT scans in metastatic melanoma patients commencing immune checkpoint inhibitor therapy and to determine the average time to confirmed 18F‐FDG PET/CT response in the pseudoprogression cohort identified.
Citation format
MACILWRAITH, Philip, et al. Incidence of reported pseudoprogression on 18F‐FDG PET/CT in metastatic melanoma patients undergoing immune checkpoint inhibitor immunotherapy. Journal of Medical Imaging and Radiation Oncology, 2026, 70(2): 162–168.